Please assess the completion status of the following clinical trial:

Trial Title: Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* LMT ineligible~* Participants must meet the lipid criteria of low to moderate CHD risk as defined by National Cholesterol Education Program Adult Treatment Panel III Framingham Point Scores (NCEP ATP III)~* HDL-C \<40 mg/dL (1.03 mmol/L) in males and \<50 mg/dL (1.29 mmol/L) in females~* Triglyceride (TG) level \<300 mg/dL (3.39 mmol/L).~* Fasting serum glucose (FSG) at Visit 1 AND Visit 2 \<126 mg/dL (\<7 mmol/L)~* Hemoglobin A1c (HbA1c) level \<6.5%~* Participant willing to use acceptable method of contraception during the study, including the 14-day follow-up period~Exclusion criteria:~* History of malignancy ≤5 years prior to signing informed consent, except for adequately-treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Participation in a study with an investigational compound (non-lipid-modifying) within 30 days~* Pregnant, breastfeeding, or expecting to conceive, or father a child during the study, including the 14-day follow-up period~* Consumption of more than 3 alcoholic drinks on any given day or more than 14 drinks per week~* Engages in or plans to engage in vigorous exercise or an aggressive diet regimen during the study~* Diabetes mellitus, based on medical history, FSG ≥126 mg/dL (7 mmol/L), and HbA1c ≥6.5%~* Risk factors for coronary heart disease~* Active or chronic hepatobiliary or hepatic disease~* Active peptic ulcer disease within 3 months of Visit 1~* History of hypersensitivity or allergic reaction to niacin or niacin-containing products~* Episode of gout within 1 year of Visit 1, unless currently stable on allopurinol~* Taking an LMT (including statins, bile acid sequestrants, fibrates and niacin \>50 mg as monotherapy or coadministered with other LMTs)~* Use of over-the- counter or traditional medicine (e.g. red yeast rice products) for lipid-lowering~* Receiving treatment with systemic corticosteroids (unless on stable therapy for at lest 6 weeks for replacement for pituitary/adrenal/hypogonadal disease)~* Uncontrolled illness or infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ERN/LRPT group (Type: EXPERIMENTAL): All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive ERN/LRPT for 16 weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive placebo for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).